VisionGate Competitors, Revenue, Alternatives and Pricing

Claim your profile


Phoenix, AZ USA
Total Funding:N/A
Lead Investor(s):N/A

Estimated Revenue & Financials

  • VisionGate's estimated annual revenue is currently $5.7M per year.
  • VisionGate's estimated revenue per employee is $155,000

Employee Data

  • VisionGate has 37 Employees.
  • VisionGate grew their employee count by -10% last year.
  • VisionGate currently has 1 job openings.

VisionGate, Inc., is a clinical stage oncology pharmaceutical and diagnostics company with a focus on the early detection and treatment of lung cancer and bronchial dysplasia. The foundation for our diagnostics capability is the proprietary Cell-CTᅢᄁ¬ダᅡᄁ 3-Dimensional Cell Imaging and Analysis platform. The Cell-CT platform, using a process called optical computed tomography (CT), produces 3D images of individual cells with the ability to morphologically recognize over 700 structural biomarkers of normal and abnormal cells. The Cell-CT platform can process any liquid biopsy specimen and therefore has potential applicability to detect a wide range of different cancers and cancer biosignatures that could aid in identifying potential treatments using targeted pharmaceutical therapies. Our lead diagnostic product is the LuCEDᅢツᅡᆴ lung test - a non-invasive sputum-based test that detects abnormal cells which indicate lung cancer and bronchial dysplasia. LuCED lung test utilizes the Cell-CT platform and is in development for the early detection of lung cancer, bronchial dysplasia and the assessment of indeterminate pulmonary nodules (IPN). The LuCED test includes CellGazerᅢᄁ¬ダᅡᄁ application, an imaging software tool under development to facilitate cytopathology diagnosis of abnormal cell images detected by the Cell-CT platform. Our lead investigative pharmaceutical product iloprost, an oral prostacyclin analog, has progressed through an NCI-sponsored Phase 2 clinical trial. Iloprost is a potential first-in-class lung cancer prevention drug in clinical development to treat former smokers for the reduction of moderate to severe bronchial dysplasia as measured by the LuCEDᅢツᅡᆴ lung test. The LuCED test is being developed as a companion diagnostic to iloprost. The LuCED test and iloprost portfolio provides VisionGate the potential unique ability to both identify and treat patients with pre-cancerous bronchial dysplasia. Follow us on Linked In for updates and visit